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B6.A-Dysfprmd/GeneJ (BLAJ) mice model human limb-girdle muscular dystro-
phy 2B (LGMD2B), which is linked to mutations in the dysferlin (DYSF)
gene. We tested the hypothesis that, the calcium ion (Ca2+) channel blocker
diltiazem (DTZ), reduces contraction-induced skeletal muscle damage, in
BLAJ mice. We randomly assigned mice (N = 12; 3–4 month old males) to
one of two groups – DTZ (N = 6) or vehicle (VEH, distilled water, N = 6).
We conditioned mice with either DTZ or VEH for 1 week, after which, their
tibialis anterior (TA) muscles were tested for contractile torque and suscepti-
bility to injury from forced eccentric contractions. We continued dosing with
DTZ or VEH for 3 days following eccentric contractions, and then studied
torque recovery and muscle damage. We analyzed contractile torque before
eccentric contractions, immediately after eccentric contractions, and at 3 days
after eccentric contractions; and counted damaged fibers in the injured and
uninjured TA muscles. We found that DTZ improved contractile torque
before and immediately after forced eccentric contractions, but did not reduce
delayed-onset muscle damage that was observed at 3 days after eccentric
contractions.
ª 2018 The Authors. Physiological Reports published by Wiley Periodicals, Inc. on behalf of
The Physiological Society and the American Physiological Society.
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Introduction
Dysferlin-linked muscular dystrophies (a.k.a. dysfer-
linopathies) are a group of inherited diseases that cause
progressive skeletal muscle weakness and wasting, with
onset in the late-teen years (Urtizberea et al. 2008; Harris
et al. 2016). Dysferlinopathies are caused by mutations in
the dysferlin (DYSF) gene, resulting in complete or partial
absence of the protein dysferlin (Liu et al. 1998). Several
theories have been proposed regarding the pathogenesis
of dysferlinopathies, of which, one is, the presence of
unstable transverse-tubules (t-tubules) and stress-induced
alterations in Ca2+ signaling in skeletal muscle (Bansal
et al. 2003; Kesari et al. 2008; Nagaraju et al. 2008; Klinge
et al. 2010; Kerr et al. 2013; Defour et al. 2014; Demon-
breun et al. 2014; Hofhuis et al. 2017). The Ca2+ channel
blocker diltiazem (DTZ), mitigates stress-induced changes
in Ca2+ signaling, and protects dysferlin-deficient A/J
mouse muscle fibers from stress-induced cell damage,
both in vitro and in vivo (Kerr et al. 2013). The in vivo
data on the protective effect of DTZ against stress-
induced muscle fiber damage are of particular transla-
tional value, since dysferlin-deficient A/J mice sustain
severe delayed-onset muscle damage, following injurious
large-strain eccentric contractions (large-strain injury,
LSI) to the tibialis anterior (TA) muscle (Roche et al.
2010, 2012, 2015). The data from A/J mice corroborate
with the natural history of dysferlinopathies reported by
patients, with regard to intense physical exercise and/or
activity increasing muscle weakness (Angelini et al. 2011;
Moore et al. 2018; Jain Foundation Inc., 2017). However,
in addition to the dysferlin mutation, A/J mice carry sev-
eral other mutations that might affect muscle physiology
(Ho et al. 2004; The Jackson Laboratory, 2018). Further-
more, it has been reported that, dysferlin-deficient B6.A-
Dysfprmd/GeneJ (BLAJ) mice (developed by introgressing
the A/J dysferlin mutation into the B6 mouse back-
ground) do not show as much delayed-onset muscle
damage as A/J mice, at 3 days after LSI (Lostal et al.
2010; Roche et al. 2012). Therefore, the LSI model is not
ideal for preclinical screens of potential therapies for
dysferlinopathy, in mouse strains other than A/J – such
as the BLAJ strain (Roche et al. 2012). Furthermore,
the LSI model involves rapidly moving the ankle joint
of mice, from 90 to 180° of plantarflexion (1200°/sec),
causing the foot to be almost in the same plane as the
tibia at the end of the motion, raising concerns about
the range of movement being nonphysiological and
potentially injurious to the ankle-foot complex. In order
to address the issues described above, we developed a
modified protocol of in vivo eccentric contractions,
which involves plantarflexing the ankle from 90° to
160° (20° less plantarflexion than LSI), at an angular
velocity of 300°/sec (25% the velocity of LSI). Also,
instead of performing just one set of 20 repetitions as
done in LSI, in our new eccentric contractions proto-
col, we perform 40 total repetitions, in four sets of 10
repetitions each, with 2 min rest between sets. Our new
eccentric contractions protocol, referred to hereafter as
Medium Strain Forced Eccentric Exercise (MSFEE, acro-
nym pronounced “Ms. Fee”), is an eccentrically biased
adaptation of a single bout in the MacQueen progres-
sive resistance training regime (Macqueen 1954; Dutton
2011). The rationale for the increased number of reps
in the MSFEE protocol compared to the LSI protocol,
was based on pilot data, which suggested that, the 20
additional repetitions were required to consistently pro-
duce a similar loss of contractile torque as the LSI pro-
tocol (~ 50% of baseline torque), immediately after
eccentric contractions in BLAJ mice (Roche et al. 2012).
The studies described here, were designed to test the
hypothesis that diltiazem protects dysferlin-deficient




All experiments with live animals were performed at
Wayne State University (Detroit, MI), according to proto-
cols approved by the Institutional Animal Care and Use
Committee. These protocols were in accordance with the
Guide for the Care and Use of Laboratory Animals (1996,
published by National Academy Press, 2101 Constitution
Ave. NW, Washington, DC).
We studied dysferlin-deficient, male, BLAJ mice (Stock
No: 012767; The Jackson Laboratory, Bar Harbor, Maine,
USA). The BLAJ strain of mice is a well-characterized
murine model of dysferlinopathy that resembles the
human LGMD2B phenotype (Nagy et al. 2017). As the
Jain Foundation Inc. (Bellevue, WA) maintains a colony
of BLAJ mice at The Jackson Laboratory, the mice are
provided as a gift from the Jain Foundation Inc. to part-
ner laboratories.
We studied male mice, due to the availability of data
from several published and pilot studies, on the response
of control and dysferlin-null male mice to injury by
eccentric contractions (Roche et al. 2008, 2010, 2012,
2015; Millay et al. 2009b; Nagy et al. 2017). Mice were
3–4 months when we studied them, because at this age,
BLAJ mice have a mature musculoskeletal system, but
show very minimal spontaneous dystrophic changes in
their skeletal muscles – this is an important consideration
because spontaneous muscle damage might confound
exercise-induced muscle damage (Nagy et al. 2017).
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We measured contractile torque, performed MSFEE,
administered intraperitoneal injections of DTZ, and col-
lected TA muscles, under inhaled isoflurane anesthesia
(2–5% for induction; 1–4% for maintenance), in order to
reduce handling stress and pain (Tabletop Anesthesia
Machine, VetEquip, Livermore, CA). After collecting TA
muscles, we euthanized mice by cervical dislocation
(death ensured by bilateral pneumothorax) before pro-
ceeding to collect other tissues.
Research design
We randomly assigned 12 mice to one of two study
groups – namely, diltiazem-treated group (DTZ, N = 6
mice) and a vehicle-treated group (VEH, distilled water,
N = 6 mice). We chose our sample sizes based on earlier
studies, which suggested that, at Day 3 after eccentric
contractions, in order for a 10-percentage-point reduction
in the number of damaged fibers to be significant at an
alpha level of 0.05 with a power of 0.80, we would need
to study six animals per group.
We assigned a unique identification number for each
mouse included in the study, and matched the number
with an ear tagging and tail tattooing system. We condi-
tioned mice with DTZ or VEH for 7 days before exposing
them to MSFEE. On the day of MSFEE (Day 0), we
assessed baseline contractile torque, exposed mice to the
MSFEE protocol, studied immediate post-MSFEE contrac-
tile torque, and returned animals to their original cages
and then to the animal facility. We continued dosing with
DTZ or VEH on the day of MSFEE and for 3 days, there-
after. On the third day post-MSFEE (Day 3), we mea-
sured contractile torque to assess extent of recovery, and
collected tissue per approved protocols (if MSFEE was
performed on Monday, then Day 3 was Thursday).
Details on how we dosed animals, studied contractile tor-
que, performed MSFEE, processed tissue for histological
studies, and quantified muscle damage, are described in
specific subsections of the Methods.
Contractile torque measurement and MSFEE
We measured contractile torque of the ankle dorsiflexors
of the left hindlimb and exposed this muscle group to
eccentrically biased forced exercise (MSFEE, 40 repeti-
tions, 90–160° ankle plantarflexion during tetanic con-
traction of dorsiflexors). We measured contractile torque
and performed MSFEE with a custom-built rig, which is
a scaled down version of an isokinetic dynamometer that
is used for human testing and training (Bloch et al.
2012). Our rig is currently set up to study the ankle dor-
siflexors of the left hindlimb of mice. As described in the
Introduction, the MSFEE protocol is a refinement of the
large-strain injury (LSI) model that has been described
and referenced in many publications (Roche et al. 2008,
2010, 2012, 2015; Millay et al. 2009b; Lovering et al.
2011; Lostal et al. 2012; Kerr et al. 2013). Images of our
dynamometry rig are provided in Figure 1. We measured
baseline contractile torque before MSFEE, the amount of
torque lost immediately after MSFEE (Day 0, ~10 min
post-MSFEE), and the extent of torque recovery at 3 days
post-MSFEE (Day 3). We chose Day 3 for follow-up stud-
ies, because delayed-onset muscle damage from in vivo
eccentric contractions peaks at this time point in dysfer-
lin-deficient A/J mouse muscle, and this phenotype pro-
vides a reliable set of outcome measures for preclinical
testing of experimental therapies (Millay et al. 2009b;
Roche et al. 2010, 2015; Lostal et al. 2012; Kerr et al.
2013).
Before measuring contractile torque or performing
MSFEE, we removed fur from the animal’s leg and lower
thigh, and cleaned the area with three alternating scrubs
of povidone iodine solution and 70% ethanol. We then
passed a 26 G (1/2″) hypodermic needle (surgical steel)
through the proximal tibial metaphysis (medial to lateral),
removed the plastic hub of the needle, and held the ends
of the needle in an alligator clamp, which was attached to
a limb stabilization assembly on the dynamometry rig
(Fig. 1A and B). We placed the animal in a supine posi-
tion on the rig, and strapped its foot to a footplate that
was linked in series to a torque transducer and a stepper
motor (Fig. 1A–F). The movement of the stepper motor
and acquisition of torque, were achieved through custom-
written routines in Labview 2014 (National Instruments,
Austin, TX). We elicited contractions of the ankle dorsi-
flexors by electrically stimulating the common peroneal
nerve with a transcutaneous bipolar electrode (BS4 50–
6824, Harvard Apparatus, Holliston, MA) connected to
an S48 square pulse stimulator (Grass Instruments, West
Warwick, RI) through a PSIU6 stimulation isolation unit
(Grass Instruments). We delivered pulses that were
0.1 msec in duration and adjusted the pulse amplitude in
order to achieve maximal twitch torque in the ankle dor-
siflexors (Fig. 1G). We used incremental pulse frequencies
to generate a torque-frequency curve. Maximal fused
tetany occurred typically around 150 Hz, due to which,
this stimulation frequency was used for eccentric contrac-
tions during MSFEE (Fig. 1H–I).
For each eccentric contraction during MSFEE, we
induced a tetanic contraction in the ankle dorsiflexors,
and superimposed a stretch on the dorsiflexors by pas-
sively plantarflexing the ankle with the stepper motor
(90–160°) at an angular velocity of 300°/sec (Fig. 1C–F).
For each set, 10 eccentric contractions were performed at
~1 contraction every 10 sec; and a total of four sets were
performed with 2 min rest between sets.
ª 2018 The Authors. Physiological Reports published by Wiley Periodicals, Inc. on behalf of
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The term “forced exercise” is applicable for exercise
that is not performed voluntarily – such as, passive pedal-
ing on a bicycle or similar experimental device (Houle
et al. 1999; Ridgel et al. 2009; Beall et al. 2013). There-
fore, the use of the term “Forced Eccentric Exercise” in
MSFEE, is appropriate and accurate. We prefer the term
“Forced Eccentric Exercise” to the term “Eccentric
Injury”, because the MSFEE protocol follows a very speci-
fic set of parameters pertaining to the range of foot
movement, the angular velocity of movement, the
numbers of sets and repetitions of contractions, and the
duration of rest between sets of contractions – all of
which, are characteristic of an exercise protocol, and are
in contrast to intentional injury models that involve
eccentric contractions, mechanical impact, cryoinjury, or
myotoxins (Lovering et al. 2005, 2007; Deane et al. 2014;
Aguilar et al. 2015; Hardy et al. 2016). Furthermore,
injury from MSFEE is a secondary consequence of forced
exercise, and not the primary intent. It so happens that,






Figure 1. Setup for in vivo torque measurement and MSFEE. We measured contractile torque of the dorsiflexors of the left hindlimb and
performed MSFEE on this muscle group with a custom-built dynamometer (A and B). We elicited contractions of the dorsiflexors group of
muscles, in which the prime mover is the TA muscle, by depolarizing the common peroneal nerve with a bipolar transcutaneous electrode (A).
To perform forced eccentric contractions during MSFEE, we tetanically stimulated the dorsiflexors muscles, and forced the foot into
plantarflexion (90–160°) with a stepper motor (B–F). We were able to trigger the electrical stimulator, control the motion of the stepper motor,
and record torque data with custom-written software. Representative torque traces for a single twitch, a maximal tetanic contraction, and a
forced eccentric contraction, are shown in panels G, H, and I respectively. A single bout of MSFEE involved 40 eccentric contractions,
performed in four sets of 10 repetitions, with 2 min rest between sets.
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sustain large amounts of acute or delayed-onset muscle
damage from forced eccentric contractions – examples:
dystrophin-deficient (mdx mouse model) muscle for
acute muscle damage, and dysferlin-deficient (A/J, BLAJ,
SJL/J, B10.SJL mouse models) muscle for delayed-onset
muscle damage (Roche et al. 2012).
Dosing with DTZ
We administered DTZ by intraperitoneal injection at a
dosage of 72 mg/kg/day (Matsumura et al. 2009; Kerr
et al. 2013). We dissolved 72 mg DTZ (Cat# 0685,
Tocris, Minneapolis, MN) in 10 mL distilled water, vor-
tex-mixed the solution, and sterile-filtered it. We ali-
quoted the sterile DTZ solution into 1.5 mL conical
tubes and stored the tubes at 20°C until ready for use.
Prior to injection, we allowed DTZ to thaw at 4°C, vor-
tex-mixed the solution, and injected 10 lL/g (body
weight) of each animal. We preconditioned animals for
7 days before MSFEE, because we have observed that,
mice show increased sensitivity to inhaled isoflurane
when given DTZ for the first time; incidentally, this also
allows us to study the effects of short-term dosing with
DTZ on muscle physiology (Broadbent et al. 1985; Carce-
les et al. 1989; Drugs.com, 2018). On the day of MSFEE,
we gave animals 60% of the daily dose ~15 min before
MSFEE and 60% of the dose immediately after MSFEE.
The split dose of DTZ, before and after MSFEE, was to
reduce the risk of excessive cardiorespiratory depression
during MSFEE under isoflurane anesthesia (Broadbent
et al. 1985; Carceles et al. 1989; Drugs.com, 2018). Fur-
thermore, since 86.4% mg/kg/day (120% of 72 mg/kg/
day) is below the toxic dose of DTZ for mice, we admin-
istered 20% more DTZ than the daily dose, with the
hope of mitigating acute muscle damage (Drugs.com,
2018). We administered sterile-filtered distilled water
alone to the VEH group, similar to how we administered
DTZ.
Histological studies
After collecting torque data at 3 days post-MSFEE, we
collected the exercised (left) and unexercised (right) tib-
ialis anterior (TA) muscles, since the TA is the primary
ankle dorsiflexor and the largest muscle in this group
(Ingalls et al. 2004). We briefly dipped the muscles in
mineral oil for cryoprotection, blotted off the excess oil
with lab wipes, placed the muscles on pieces of alu-
minum foil, snap froze them by rapidly immersing them
in liquid nitrogen, and stored them in cryogenic vials at
80°C.
To evaluate the general morphology of the TA and
quantify myofiber damage, we performed hematoxylin
and eosin (H&E) staining on 5 lm cross sections as
described (Roche et al. 2011, 2015; Begam et al. 2016).
On additional TA muscle sections prepared as above, we
assessed sarcolemmal and myofiber damage, respectively,
based on the presence of mouse immunoglobulin G (IgG
(+)) and loss of desmin labeling (desmin()) in the myo-
plasm of myofibers, as described (Begam et al. 2016).
We captured 12 digital images of each TA muscle
cross-section made from the mid-belly of the muscle
(209 objective). This method helped sample data across
the cross-section of an entire TA muscle by moving in a
grid-like fashion. We counted the total number of fibers
(~2200 fibers per TA) and the number of damaged fibers
for each muscle, and calculated the percentage of dam-
aged fibers in each muscle (damaged fibers/total
fibers*100).
Statistical methods
We performed statistical analyses with IBM SPSS Statistics
for Windows software (Version 25.0, IBM Corp. Armonk,
NY). Since, our torque and histological data were not
normally distributed, we performed nonparametric testing
(Mann–Whitney U test) to ascertain if there were signifi-
cant differences between the DTZ and VEH groups. For
all statistical tests, the alpha level was set at 0.05, such
that P-values <0.05 were considered significant. All data
are reported as mean  standard deviation (SD). For raw
pre-MSFEE torque data and histological data, scatter-plots
of individual data points, are also shown. Group means




Our baseline torque data (pre-MSFEE torque data) indi-
cate that, the DTZ group produced higher maximum
twitch torque than the VEH group; however, there was
no difference in maximum tetanic torque, between the
DTZ and VEH groups (Fig. 2A). Our baseline torque-fre-
quency data indicate that, at low stimulation frequencies
(1–30 Hz), there was a significant difference between the
DTZ and VEH groups (Fig. 2B, Table S1).
The torque-frequency data collected immediately after
MSFEE indicate that, for stimulation frequencies up to
100 Hz, the DTZ group produced higher contractile tor-
ques (Fig. 2C, Table S2).
The torque-frequency data collected at Day 3 post-
MSFEE indicate that, except for the 10 Hz stimulation
frequency, there was no difference in contractile torque
between the DTZ and VEH groups (Fig. 2D, Table S3).
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Histological data
Representative images from the histological data that
were studied, are presented in Fig. 3A–F. The data show
extensive myofiber damage, which can be visualized
through H&E staining (pale and disrupted cytoplasm of
damaged myofibers, Fig. 3A and B), IgG labeling (IgG
inclusion in damaged myofibers, Fig. 3C and D), and
desmin labeling (loss of desmin in damaged myofibers,
Fig. 3E and F). Since H&E staining, and IgG and des-
min colabeling, were performed on serial cross-sections
of the same TA muscle, the same set of myofibers can
be visualized in panels A, C, E (DTZ) and panels B, D,
F (VEH) of Figure 3. The superimposed asterisks (*) in
the image panels, denote the same subset of damaged
fibers in serial sections (Fig. 3A, C, E, and B, D, F
respectively).
Our quantitative analysis of images obtained from
H&E staining, indicates that, there was no significant dif-
ference between DTZ and VEH groups, for muscle dam-
age, at 3 days post-MSFEE (Fig. 3G, Table S4). Likewise,
our quantitative analysis of images obtained from and
IgG and desmin colabeling, indicates that, there was no
significant difference between DTZ and VEH groups, for
muscle damage (IgG inclusion and desmin loss) at 3 days
post-MSFEE (Fig. 3H, Table S5).
Discussion
We wanted to ascertain if the L-type Ca2+ channel blocker
DTZ, can reduce delayed-onset muscle damage after
eccentric contractions, in dysferlin-deficient BLAJ mice.
Our studies were a follow-up to an earlier report, which
suggested that, DTZ stabilized stress-induced changes in
t-tubules and reduced delayed-onset muscle damage in
dysferlin-deficient A/J mice (Kerr et al. 2013). In order to
study BLAJ mice, we had to develop a new in vivo model
of eccentric contractions, since the previously employed
LSI model of eccentric contractions did not produce suffi-
cient amounts of delayed-onset muscle damage in dysfer-
linopathic mouse strains other than the A/J strain (Roche
et al. 2012). We therefore developed the MSFEE protocol
of eccentrically-biased forced exercise, which uses parame-
ters that are more functionally relevant than LSI
Figure 2. DTZ improves contractile torque before and immediately after MSFEE, but does not improve recovery at 3 days post-MSFEE. DTZ
increased baseline twitch torque (*), but did not increase baseline tetanic torque (A). Pre-MSFEE torque-frequency data suggest that, DTZ
improves contractile torque at low frequencies (*, 1–30 Hz), but not at stimulation frequencies higher than 30 Hz (B). The frequency labeled
reverse 1 Hz (Rev 1 Hz), is a twitch that is induced after the last tetanic contraction, in order to assess post-tetanic changes in twitch torque
(B–D). Torque data collected immediately after MSFEE suggest that, DTZ offers significant protection against acute torque loss from MSFEE
(*, C). However, the protection against acute torque loss following MSFEE, is not seen at frequencies higher than 100 Hz (C). Torque data
collected at 3 days post-MSFEE suggest that, DTZ does not help improve torque recovery, except at the stimulation frequency of 10 Hz (D).
Data are reported as mean  SD. Asterisks denote a significant difference between DTZ and VEH.
2018 | Vol. 6 | Iss. 11 | e13727
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(described in Introduction and Methods), and produces
consistent delayed-onset muscle damage of a magnitude
that is a large enough to study the effects of DTZ in BLAJ
mice.
Our torque data suggest that DTZ does improve base-
line contractile function of BLAJ muscle. Specifically, tor-
ques at low stimulation frequencies (1–30 Hz), were





Figure 3. DTZ does not reduce delayed-onset muscle damage at 3 days post-MSFEE. Our data suggest that, extensive myofiber damage can
be detected at 3 days post-MSFEE in BLAJ mice, irrespective of whether the animals are given DTZ or VEH (A–F). This damage can be detected
by the presence of myofibers with pale and/or disrupted cytoplasm in H&E stained sections (A and B), and by the inclusion of endogenous IgG
(C and D) and loss of desmin (E and F) within myofibers. Since H&E staining, and IgG and desmin colabeling, were performed on serial cross-
sections of the same TA muscle; the superimposed asterisks (*) in the image panels, denote the same subset of damaged fibers in panels A, C,
E (DTZ) and panels B, D, F (VEH). Scale bar = 100 lm. Our quantitative analyses on images, such as, panels A–F, are shown in panels G
(damaged fiber counts from H&E stained sections) and H (damaged fiber counts from IgG- and desmin-labeled sections). Our data suggest that,
at 3 days post-MSFEE, DTZ does not reduce myofiber damage, as assessed by H&E staining (G) or IgG and desmin labeling (H). Data are
reported as mean  SD.
ª 2018 The Authors. Physiological Reports published by Wiley Periodicals, Inc. on behalf of
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did not improve the maximum tetanic torque (typically
achieved at 125–150 Hz). These data suggest that DTZ is
unlikely to improve maximum voluntary contraction
(MVC) in patients with dysferlinopathies, and therefore
not improve functional muscle strength (Horlings et al.
2008; Orr 2010; Shimada et al. 2010). We, however, did
find that, DTZ offered significant protection against acute
torque loss, soon after MSFEE (1–100 Hz), which might
be of translational value; in relation to protection of dys-
ferlin-deficient from damage that might be induced by
low-intensity eccentric loading, during modified activities
of daily living. At 3 days post-MSFEE, where we hoped to
see better torque production in the DTZ group than the
VEH group, we did not see a significant difference in
contractile torque for any of the stimulation frequencies
except 10 Hz. These findings suggest that DTZ might be
capable of producing some improvement in baseline con-
tractile properties of dysferlinopathic muscle, and might
even be able to protect muscle against acute torque loss
from eccentric contractions, but that it does not promote
faster recovery of contractile function at 3 days after inju-
rious eccentric contractions.
Our histological data support the conclusions drawn
from torque data collected at 3 days post-MSFEE. We
had predicted that DTZ would reduce the extent of
delayed-onset muscle damage observed at 3 days post-
MSFEE, similar to what we had seen after LSI in A/J
mice. However, we observed that DTZ did not offer pro-
tection against muscle damage from MSFEE in BLAJ
mice. Both DTZ and VEH groups had ~40% damaged
myofibers in the exercised TA muscle, which validated the
MSFEE protocol as suitable for preclinical studies of BLAJ
mice, since it consistently produces extensive myofiber
damage.
Our current studies serve to temper earlier conclusions,
drawn from studies on dysferlin-deficient A/J mice, for
the protective effects of DTZ on dysferlinopathic muscle
(Kerr et al. 2013). As concluded in an earlier study, our
current studies support the notion that, the pathology
dysferlin-deficiency might be much more complex than a
simple failure of sarcolemmal resealing or t-tubule insta-
bility, even though these are salient features of dysferlin-
deficient muscle cells (Lostal et al. 2012). Furthermore,
even though DTZ might confer some benefit on dysfer-
linopathic muscle; the recent concerns about calcium
channel blockers being associated with an increased inci-
dence of mood disorders, must be taken into considera-
tion, if and when calcium channel blockers are prescribed
as a pharmacological intervention for dysferlinopathies
(Boal et al. 2016).
Our studies also serve to emphasize the value of mus-
cle-injury-prevention in patients with dysferlinopathies.
Since a large percentage of patients with dysferlinopathies
are known to have athletic prowess during the years prior
to onset of muscle weakness, it is not uncommon for
patients to exercise more, when they start developing
symptoms (Harris et al. 2016; Moore et al. 2018; Jain
Foundation Inc., 2017). The evidence so far suggests that,
like most other muscular dystrophies (other than some
congenital muscular dystrophies), dysferlinopathies are
progressive conditions, and therefore, cannot be reversed
by exercise. The fact that dysferlinopathies are progressive
conditions, should encourage the focus of rehabilitative
interventions, to be more on slowing down the natural
progression of muscle weakness and wasting, rather than
increasing muscle strength and walking capacity at the
risk of causing irreversible muscle damage. Preserving
functional muscle mass for as long as possible, prevent-
ing joint contractures, and maintaining the central ner-
vous system’s synaptic connections for functional
movement, might help optimize patient-readiness for
promising gene therapies that are under intense investi-
gation (Lostal et al. 2010; Long et al. 2014; Sondergaard
et al. 2015; Nelson et al. 2016; Robinson-Hamm and
Gersbach 2016; Tabebordbar et al. 2016; Benedetti et al.
2017). In the context of our current set of studies, it
appears that, DTZ is not likely to reduce the damage
that is induced by a moderately intense bout of repeti-
tive eccentric loading, in dysferlin-deficient mammalian
skeletal muscle. Therefore, even if a patient with dysfer-
linopathy takes DTZ, it would still be important to
choose muscle contractions (example: concentric vs.
eccentric) and exercise loads (example: low repetition vs.
high repetition) to obtain the benefits of exercise with-
out causing extensive muscle damage (Roche et al. 2010;
Biondi et al. 2013).
The translational significance of our findings is that,
DTZ might be able to improve baseline contractile prop-
erties of skeletal muscle in patients with dysferlinopathies,
but might not be able to mitigate contraction-induced
muscle damage from a bout of moderately intense eccen-
tric contractions. Therefore, even if patients with dysfer-
linopathies take a calcium channel blocker like DTZ for
cardiovascular comorbidities and/or for improved muscle
function; they are likely to continue to be at risk for
developing contraction-induced muscle damage, if they
perform activities that involve intense and repetitive
eccentric muscle loading (Biondi et al. 2013).
Even though our current study focused on the potential
beneficial effects of DTZ on dysferlin-linked muscular
dystrophy, our findings might also be of relevance to
other muscular dystrophies (Phillips and Quinlivan 2008;
Matsumura et al. 2009). Although the primary pathologi-
cal bases for progressive muscle weakness and wasting dif-
fer between different types of muscular dystrophy; there
is consensus that, irrespective of the type of muscular
2018 | Vol. 6 | Iss. 11 | e13727
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dystrophy, myofiber death is ultimately linked to elevated
Ca2+ levels in the cytoplasm of muscle fibers (Millay et al.
2009a; Burr and Molkentin 2015). Therefore, the predic-
tion would be that, blocking the entry of Ca2+ from the
extracellular environment into the myoplasm with DTZ,
should reduce the dystrophic phenotype in other muscu-
lar dystrophies (example: Duchenne muscular dystrophy).
However, despite promising preclinical results, clinical
data suggest that DTZ does not significantly alter func-
tional outcomes in patients with Duchenne muscular dys-
trophy (Phillips and Quinlivan 2008; Matsumura et al.
2009). Similar to our discussion, above, on the role of
exercise for dysferlinopathies; it is likely that, the patho-
logical processes underlying muscular dystrophies are too
severe, for drugs like DTZ, to significantly alter functional
outcomes in clinical trials. However, pharmacological
agents that effectively inhibit dystrophic muscle loss in
preclinical models, might still have a role in preserving
muscle mass, and optimizing patient-readiness for
promising gene therapies, even if they don’t significantly
improve standard functional outcomes (example: 6-min
walk test, timed up and go test, etc.). Single case studies
on patients with dysferlinopathies who have been pre-
scribed DTZ, might provide insights into whether large
clinical trials are warranted.
Conclusion
Diltiazem improves contractile properties of dysferlin-
deficient BLAJ mouse muscle, after 7 days of dosing. Dil-
tiazem also reduces the acute loss of contractile torque
immediately after eccentric contractions. However, dilti-
azem does not reduce delayed-onset muscle damage
observed at 3 days after eccentric contractions.
Conflict of Interest
The authors have no conflicts to declare.
References
Aguilar, C. A., A. Shcherbina, D. O. Ricke, R. Pop, C. T.
Carrigan, C. A. Gifford, et al. 2015. In vivo monitoring of
transcriptional dynamics after lower-limb muscle injury
enables quantitative classification of healing. Sci. Rep.
5:13885.
Angelini, C., E. Peterle, A. Gaiani, L. Bortolussi, and C.
Borsato. 2011. Dysferlinopathy course and sportive
activity: clues for possible treatment. Acta Myol. 30:127–
132.
Bansal, D., K. Miyake, S. S. Vogel, S. Groh, C. C. Chen, R.
Williamson, et al. 2003. Defective membrane repair in
dysferlin-deficient muscular dystrophy. Nature 423:168–
172.
Beall, E. B., M. J. Lowe, J. L. Alberts, A. M. Frankemolle, A. K.
Thota, C. Shah, et al. 2013. The effect of forced-exercise
therapy for Parkinson’s disease on motor cortex functional
connectivity. Brain Connect 3:190–198.
Begam, M., V. M. Abro, A. L. Mueller, and J. A. Roche. 2016.
Sodium 4-phenylbutyrate reduces myofiber damage in a
mouse model of Duchenne muscular dystrophy. Appl.
Physiol. Nutr. Metab. 41:1108–1111.
Benedetti, S., N. Uno, H. Hoshiya, M. Ragazzi, G. Ferrari, Y.
Kazuki, et al. 2017. Reversible immortalisation enables
genetic correction of human muscle progenitors and
engineering of next-generation human artificial
chromosomes for Duchenne muscular dystrophy. EMBO
Mol. Med. 10:254–275.
Biondi, O., M. Villemeur, A. Marchand, F. Chretien, N. Bourg,
R. K. Gherardi, et al. 2013. Dual effects of exercise in
dysferlinopathy. Am. J. Pathol. 182:2298–2309.
Bloch, R. J., J. A. Roche, R. M. Lovering, P. G. De Deyne, W.
Tang, V. T. Grubbs, et al. 2012. Small-animal unit for
muscle injury, muscle testing and muscle training in vivo.
Google Patents.
Boal, A. H., D. J. Smith, L. McCallum, S. Muir, R. M. Touyz,
A. F. Dominiczak, et al. 2016. Monotherapy with major
antihypertensive drug classes and risk of hospital admissions
for mood disorders. Hypertension 68:1132–1138.
Broadbent, M. P., P. C. Swan, and R. M. Jones. 1985.
Interactions between diltiazem and isoflurane: an in vitro
investigation in Isolated guineapig atria. Br. J. Anaesth.
57:1018–1021.
Burr, A. R., and J. D. Molkentin. 2015. Genetic evidence in the
mouse solidifies the calcium hypothesis of myofiber death in
muscular dystrophy. Cell Death Differ. 22:1402–1412.
Carceles, M. D., F. S. Miralles, M. L. Laorden, and J.
Hernandez. 1989. Interactions between diltiazem and
inhalation anaesthetics in the isolated heart. Br. J. Anaesth.
63:321–325.
Deane, M. N., M. Gregory, and M. Mars. 2014. The creation
of a measurable contusion injury in skeletal muscle. J. S.
Afr. Vet. Assoc. 85:1031.
Defour, A., J. H. Van der Meulen, R. Bhat, A. Bigot, R. Bashir,
K. Nagaraju, et al. 2014. Dysferlin regulates cell membrane
repair by facilitating injury-triggered acid sphingomyelinase
secretion. Cell Death Dis. 5:e1306.
Demonbreun, A. R., A. E. Rossi, M. G. Alvarez, K. E.
Swanson, H. K. Deveaux, J. U. Earley, et al. 2014. Dysferlin
and myoferlin regulate transverse tubule formation and
glycerol sensitivity. Am. J. Pathol. 184:248–259.
Drugs.com. 2018. Diltiazem https://www.drugs.com/diltiazem.
html. [04/30/18, 2018].
Dutton, M. 2011. Orthopaedics for the physical therapist
assistant. Jones & Bartlett Learning, Sudbury, MA, p. xxv,
733 p.
Hardy, D., A. Besnard, M. Latil, G. Jouvion, D. Briand, C.
Thepenier, et al. 2016. Comparative study of injury models
ª 2018 The Authors. Physiological Reports published by Wiley Periodicals, Inc. on behalf of
The Physiological Society and the American Physiological Society.
2018 | Vol. 6 | Iss. 11 | e13727
Page 9
M. Begam et al. Diltiazem and Dysferlin-Deficiency
for studying muscle regeneration in mice. PLoS ONE 11:
e0147198.
Harris, E., C. L. Bladen, A. Mayhew, M. James, K. Bettinson,
U. Moore, et al. 2016. The clinical outcome study for
dysferlinopathy: an international multicenter study. Neurol.
Genet. 2:e89.
Ho, M., C. M. Post, L. R. Donahue, H. G. Lidov, R. T.
Bronson, H. Goolsby, et al. 2004. Disruption of muscle
membrane and phenotype divergence in two novel mouse
models of dysferlin deficiency. Hum. Mol. Genet. 13:1999–
2010.
Hofhuis, J., K. Bersch, R. Bussenschutt, M. Drzymalski, D.
Liebetanz, V. O. Nikolaev, et al. 2017. Dysferlin mediates
membrane tubulation and links T-tubule biogenesis to
muscular dystrophy. J. Cell Sci. 130:841–852.
Horlings, C. G., B. G. van Engelen, J. H. Allum, and B. R.
Bloem. 2008. A weak balance: the contribution of muscle
weakness to postural instability and falls. Nat. Clin. Pract.
Neurol. 4:504–515.
Houle, J. D., K. Morris, R. D. Skinner, E. Garcia-Rill, and C.
A. Peterson. 1999. Effects of fetal spinal cord tissue
transplants and cycling exercise on the soleus muscle in
spinalized rats. Muscle Nerve 22:846–856.
Ingalls, C. P., G. L. Warren, J. Z. Zhang, S. L. Hamilton, and
R. B. Armstrong. 2004. Dihydropyridine and ryanodine
receptor binding after eccentric contractions in mouse
skeletal muscle. J. Appl. Physiol. 96:1619–1625.
Jain Foundation Inc. 2017. https://www.jain-foundation.org/pa
tient-physician-resources/patient-stories/patient-stories-bec
ky. [12/22/17, 2017].
Kerr, J. P., A. P. Ziman, A. L. Mueller, J. M. Muriel, E.
Kleinhans-Welte, J. D. Gumerson, et al. 2013. Dysferlin
stabilizes stress-induced Ca2+ signaling in the transverse
tubule membrane. Proc. Natl Acad. Sci. USA 110:20831–
20836.
Kesari, A., M. Fukuda, S. Knoblach, R. Bashir, G. A. Nader,
D. Rao, et al. 2008. Dysferlin deficiency shows
compensatory induction of Rab27A/Slp2a that may
contribute to inflammatory onset. Am. J. Pathol.
173:1476–1487.
Klinge, L., J. Harris, C. Sewry, R. Charlton, L. Anderson, S.
Laval, et al. 2010. Dysferlin associates with the developing
T-tubule system in rodent and human skeletal muscle.
Muscle Nerve 41:166–173.
The Jackson Laboratory. 2018. A/J. Stock No: 000646 https://
www.jax.org/strain/000646. [05/05/18, 2018].
Liu, J., M. Aoki, I. Illa, C. Wu, M. Fardeau, C. Angelini, et al.
1998. Dysferlin, a novel skeletal muscle gene, is mutated in
Miyoshi myopathy and limb girdle muscular dystrophy.
Nat. Genet. 20:31–36.
Long, C., J. R. McAnally, J. M. Shelton, A. A. Mireault, R.
Bassel-Duby, and E. N. Olson. 2014. Prevention of muscular
dystrophy in mice by CRISPR/Cas9-mediated editing of
germline DNA. Science 345:1184–1188.
Lostal, W., M. Bartoli, N. Bourg, C. Roudaut, A. Bentaib, K.
Miyake, et al. 2010. Efficient recovery of dysferlin deficiency
by dual adeno-associated vector-mediated gene transfer.
Hum. Mol. Genet. 19:1897–1907.
Lostal, W., M. Bartoli, C. Roudaut, N. Bourg, M. Krahn, M.
Pryadkina, et al. 2012. Lack of correlation between
outcomes of membrane repair assay and correction of
dystrophic changes in experimental therapeutic strategy in
dysferlinopathy. PLoS ONE 7:e38036.
Lovering, R. M., M. Hakim, C. T. 3rd Moorman, and P. G. De
Deyne. 2005. The contribution of contractile pre-activation
to loss of function after a single lengthening contraction. J.
Biomech. 38:1501–1507.
Lovering, R. M., J. A. Roche, R. J. Bloch, and P. G. De Deyne.
2007. Recovery of function in skeletal muscle following 2
different contraction-induced injuries. Arch. Phys. Med.
Rehabil. 88:617–625.
Lovering, R. M., J. A. Roche, M. H. Goodall, B. B. Clark, and
A. McMillan. 2011. An in vivo rodent model of contraction-
induced injury and non-invasive monitoring of recovery. J.
Vis. Exp. https://doi.org/10.3791/2782
Macqueen, I. J. 1954. Recent advances in the technique of
progressive resistance exercise. Br. Med. J. 2:1193–1198.
Matsumura, C. Y., A. Pertille, T. C. Albuquerque, H. Santo
Neto, and M. J. Marques. 2009. Diltiazem and verapamil
protect dystrophin-deficient muscle fibers of MDX mice
from degeneration: a potential role in calcium buffering and
sarcolemmal stability. Muscle Nerve 39:167–176.
Millay, D. P., S. A. Goonasekera, M. A. Sargent, M. Maillet, B.
J. Aronow, and J. D. Molkentin. 2009a. Calcium influx is
sufficient to induce muscular dystrophy through a TRPC-
dependent mechanism. Proc. Natl Acad. Sci. USA
106:19023–19028.
Millay, D. P., M. Maillet, J. A. Roche, M. A. Sargent, E. M.
McNally, R. J. Bloch, et al. 2009b. Genetic manipulation of
dysferlin expression in skeletal muscle: novel insights into
muscular dystrophy. Am. J. Pathol. 175:1817–1823.
Moore, U. R., M. Jacobs, R. Fernandez-Torron, J. Jang, M. K.
James, A. Mayhew, et al. 2018. Teenage exercise is
associated with earlier symptom onset in dysferlinopathy: a
retrospective cohort study. J. Neurol. Neurosurg. Psychiatry.
https://doi.org/10.1136/jnnp-2017-317329
Nagaraju, K., R. Rawat, E. Veszelovszky, R. Thapliyal, A.
Kesari, S. Sparks, et al. 2008. Dysferlin deficiency enhances
monocyte phagocytosis: a model for the inflammatory onset
of limb-girdle muscular dystrophy 2B. Am. J. Pathol.
172:774–785.
Nagy, N., R. J. Nonneman, T. Llanga, C. F. Dial, N. V.
Riddick, T. Hampton, et al. 2017. Hip region muscular
dystrophy and emergence of motor deficits in dysferlin-
deficient Bla/J mice. Physiol. Rep. 5. https://doi.org/10.
14814/phy2.13173
Nelson, C. E., C. H. Hakim, D. G. Ousterout, P. I. Thakore, E.
A. Moreb, R. M. Castellanos Rivera, et al. 2016. In vivo
2018 | Vol. 6 | Iss. 11 | e13727
Page 10
ª 2018 The Authors. Physiological Reports published by Wiley Periodicals, Inc. on behalf of
The Physiological Society and the American Physiological Society.
Diltiazem and Dysferlin-Deficiency M. Begam et al.
genome editing improves muscle function in a mouse
model of Duchenne muscular dystrophy. Science 351:403–
407.
Orr, R. 2010. Contribution of muscle weakness to postural
instability in the elderly. A systematic review. Eur. J. Phys.
Rehabil. Med. 46:183–220.
Phillips, M. F., and R. Quinlivan. 2008. Calcium antagonists
for Duchenne muscular dystrophy. Cochrane Database Syst.
Rev. (4):CD004571. https://doi.org/10.1002/14651858.
CD004571.pub2.
Ridgel, A. L., J. L. Vitek, and J. L. Alberts. 2009. Forced,
not voluntary, exercise improves motor function in
Parkinson’s disease patients. Neurorehabil. Neural Repair
23:600–608.
Robinson-Hamm, J. N., and C. A. Gersbach. 2016. Gene
therapies that restore dystrophin expression for the
treatment of Duchenne muscular dystrophy. Hum. Genet.
135:1029–1040.
Roche, J. A., R. M. Lovering, and R. J. Bloch. 2008. Impaired
recovery of dysferlin-null skeletal muscle after contraction-
induced injury in vivo. NeuroReport 19:1579–1584.
Roche, J. A., R. M. Lovering, R. Roche, L. W. Ru, P. W. Reed,
and R. J. Bloch. 2010. Extensive mononuclear infiltration
and myogenesis characterize recovery of dysferlin-null
skeletal muscle from contraction-induced injuries. Am. J.
Physiol. Cell Physiol. 298:C298–C312.
Roche, J. A., D. L. Ford-Speelman, L. W. Ru, A. L. Densmore,
R. Roche, P. W. Reed, et al. 2011. Physiological and
histological changes in skeletal muscle following in vivo
gene transfer by electroporation. Am. J. Physiol. Cell
Physiol. 301:C1239–C1250.
Roche, J. A., L. W. Ru, and R. J. Bloch. 2012. Distinct effects
of contraction-induced injury in vivo on four different
murine models of dysferlinopathy. J. Biomed. Biotechnol.
2012:134031.
Roche, J. A., M. E. Tulapurkar, A. L. Mueller, N. van Rooijen,
J. D. Hasday, R. M. Lovering, et al. 2015. Myofiber damage
precedes macrophage infiltration after in vivo injury in
dysferlin-deficient A/J mouse skeletal muscle. Am. J. Pathol.
185:1686–1698.
Shimada, H., H. Kim, H. Yoshida, Y. Yoshida, K. Saito, M.
Suzukawa, et al. 2010. Factors associated with the timed up
and go test score in elderly women. J. Phys. Ther. Sci.
22:273–278.
Sondergaard, P. C., D. A. Griffin, E. R. Pozsgai, R. W.
Johnson, W. E. Grose, K. N. Heller, et al. 2015. Dysferlin
overlap vectors restore function in dysferlinopathy animal
models. Ann. Clin. Transl. Neurol. 2:256–270.
Tabebordbar, M., K. Zhu, J. K. Cheng, W. L. Chew, J. J.
Widrick, W. X. Yan, et al. 2016. In vivo gene editing in
dystrophic mouse muscle and muscle stem cells. Science
351:407–411.
Urtizberea, J. A., G. Bassez, F. Leturcq, K. Nguyen, M. Krahn,
and N. Levy. 2008. Dysferlinopathies. Neurol. India 56:289–
297.
Supporting Information
Additional Supporting Information may be found online
in the supporting information tab for this article:
Table S1. DTZ versus VEH preinjury torque.
Table S2. DTZ versus VEH immediate postinjury torque.
Table S3. DTZ versus VEH day 3 postinjury torque.
Table S4. H&E - damaged fibers (% total).
Table S5. IgG (+) and desmin () fibers (% total).
ª 2018 The Authors. Physiological Reports published by Wiley Periodicals, Inc. on behalf of
The Physiological Society and the American Physiological Society.
2018 | Vol. 6 | Iss. 11 | e13727
Page 11
M. Begam et al. Diltiazem and Dysferlin-Deficiency
